129 related articles for article (PubMed ID: 38841800)
1. Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.
Davies N; Francis T; Oldreive C; Azam M; Wilson J; Byrd PJ; Burley M; Sharma-Oates A; Keane P; Alatawi S; Higgs MR; Rudzki Z; Ibrahim M; Perry T; Agathanggelou A; Hewitt AM; Smith E; Bonifer C; O'Connor M; Forment JV; Murray PG; Fennell E; Kelly G; Chang C; Stewart GS; Stankovic T; Kwok M; Taylor AM
Haematologica; 2024 Jun; ():. PubMed ID: 38841800
[TBL] [Abstract][Full Text] [Related]
2. ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans.
Hathcock KS; Padilla-Nash HM; Camps J; Shin DM; Triner D; Shaffer AL; Maul RW; Steinberg SM; Gearhart PJ; Staudt LM; Morse HC; Ried T; Hodes RJ
Blood; 2015 Nov; 126(20):2291-301. PubMed ID: 26400962
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.
Kim SH; Cheong JW; Park KH; Kim TS; Yang WI
Arch Pathol Lab Med; 2007 Mar; 131(3):457-67. PubMed ID: 17516749
[TBL] [Abstract][Full Text] [Related]
4. Ataxia telangiectasia gene mutations in leukaemia and lymphoma.
Boultwood J
J Clin Pathol; 2001 Jul; 54(7):512-6. PubMed ID: 11429421
[TBL] [Abstract][Full Text] [Related]
5. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
[TBL] [Abstract][Full Text] [Related]
6. Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma.
Lossos IS; Thorstenson YR; Wayne TL; Oefner PJ; Levy R; Chu G
Leuk Lymphoma; 2002 May; 43(5):1079-85. PubMed ID: 12148890
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
[TBL] [Abstract][Full Text] [Related]
8. SIRT3, a metabolic target linked to ataxia-telangiectasia mutated (ATM) gene deficiency in diffuse large B-cell lymphoma.
Bhalla K; Jaber S; Reagan K; Hamburg A; Underwood KF; Jhajharia A; Singh M; Bhandary B; Bhat S; Nanaji NM; Hisa R; McCracken C; Creasy HH; Lapidus RG; Kingsbury T; Mayer D; Polster B; Gartenhaus RB
Sci Rep; 2020 Dec; 10(1):21159. PubMed ID: 33273545
[TBL] [Abstract][Full Text] [Related]
9. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.
Restelli V; Lupi M; Chilà R; Vagni M; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Damia G; Carrassa L
Mol Cancer Ther; 2019 Jul; 18(7):1255-1264. PubMed ID: 31064869
[TBL] [Abstract][Full Text] [Related]
10. CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors.
Li H; Liu Y; Xiao Y; Wilson CN; Bai HJ; Jones MD; Wang S; DeVore JE; Maier EY; Durant ST; Boufraqech M; Weyemi U
Proc Natl Acad Sci U S A; 2023 Feb; 120(6):e2212072120. PubMed ID: 36724254
[TBL] [Abstract][Full Text] [Related]
11. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
12. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
[TBL] [Abstract][Full Text] [Related]
13. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Xu-Monette ZY; Dabaja BS; Wang X; Tu M; Manyam GC; Tzankov A; Xia Y; Zhang L; Sun R; Visco C; Dybkaer K; Yin L; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Zhao X; Winter JN; Piris MA; McDonnell TJ; Miranda RN; Li Y; Medeiros LJ; Young KH
Mod Pathol; 2015 Dec; 28(12):1555-73. PubMed ID: 26541272
[TBL] [Abstract][Full Text] [Related]
14. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
15. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.
Thomsen EA; Rovsing AB; Anderson MV; Due H; Huang J; Luo Y; Dybkaer K; Mikkelsen JG
Mol Oncol; 2020 Sep; 14(9):1978-1997. PubMed ID: 32585766
[TBL] [Abstract][Full Text] [Related]
16. Protocols for CRISPR-Cas9 Screening in Lymphoma Cell Lines.
Webster DE; Roulland S; Phelan JD
Methods Mol Biol; 2019; 1956():337-350. PubMed ID: 30779043
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.
Mo Z; Wood S; Namiranian S; Mizukoshi R; Weng S; Jang IS; Fontanillo C; Baughman JM; Silva-Torres A; Slade M; Khater M; Wang K; Rolfe M; Lu G
Blood Adv; 2021 Apr; 5(7):2027-2039. PubMed ID: 33847741
[TBL] [Abstract][Full Text] [Related]
18. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
19. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
[TBL] [Abstract][Full Text] [Related]
20. Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: correlation with clinicobiologic features.
Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Milani R; Bardi A; Minotto C; Agostini P; De Angeli C; Narducci MG; Sabbioni S; Russo G; Negrini M; Castoldi G
J Clin Oncol; 2000 Jul; 18(13):2607-14. PubMed ID: 10893293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
